title: Is the GAIN Act a turning point in new antibiotic discovery?
abstract: The United States GAIN (Generating Antibiotic Incentives Now) Act is a call to action for new antibiotic discovery and development that arises from a ground swell of concern over declining activity in this therapeutic area in the pharmaceutical sector. The GAIN Act aims to provide economic incentives for antibiotic drug discovery in the form of market exclusivity and accelerated drug approval processes. The legislation comes on the heels of nearly two decades of failure using the tools of modern drug discovery to find new antibiotic drugs. The lessons of failure are examined herein as are the prospects for a renewed effort in antibiotic drug discovery and development stimulated by new investments in both the public and private sector.
authors.affiliation: Department of Biochemistry and Biomedical Sciences, and the Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4K1, Canada. ebrown@mcmaster.ca
authors.forename: Eric D
authors.initials: ED
authors.lastname: Brown
mesh_terms: D000900:Anti-Bacterial Agents / Q000191:economics; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence; D055808:Drug Discovery / Q000191:economics / Q000331:legislation & jurisprudence / Q000639:trends; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence; D004352:Drug Resistance, Microbial; D006801:Humans; D007880:Legislation, Drug; D017149:Private Sector / Q000191:economics; D014481:United States
chemical_list: D000900:Anti-Bacterial Agents